metformin has been researched along with Papillomavirus Infections in 6 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Papillomavirus Infections: Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Paired pre- and post-treatment primary HNSCC tumor samples were stained for CD8+ and FoxP3+." | 1.91 | CD8+ and FoxP3+ T-Cell Cellular Density and Spatial Distribution After Programmed Death-Ligand 1 Check Point Inhibition. ( Alnemri, A; Argiris, A; Curry, J; Fiorella, M; Harshyne, L; Johnson, J; Linnenbach, A; Luginbuhl, A; Martinez-Outschoorn, U; Philips, R; Solomides, C; South, A; Stapp, R; Sussman, S; Tuluc, M, 2023) |
| "Metformin is an oral agent used for the management of type 2 diabetes." | 1.91 | Metformin for the Treatment of Recurrent Respiratory Papillomatosis. ( Blitzer, A; Din-Lovinescu, C, 2023) |
| "Patients aged 18-65 years with type 2 diabetes mellitus (DM) were evaluated, and cases of AIN were identified." | 1.62 | Metformin use and the risk of anal intraepithelial neoplasia in type II diabetic patients. ( D'Adamo, CR; Fang, SH; Hsu, AT; Hung, YC; Mavanur, AA; Svoboda, SM; Wolf, JH, 2021) |
| "Both metformin and curcumin have been shown to display anticancer properties." | 1.51 | Antitumour effects of metformin and curcumin in human papillomavirus positive and negative head and neck cancer cells. ( Biron, VL; Conrad, D; Harris, J; Kostiuk, M; Lindsay, C; O'Connell, DA; Seikaly, H, 2019) |
| "Most squamous cell carcinomas of the head and neck (HNSCC) exhibit a persistent activation of the PI3K-mTOR signaling pathway." | 1.42 | Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3. ( Carey, TE; Ferris, RL; Gangane, N; Gutkind, JS; Komarck, CM; Madera, D; Martin, D; McHugh, JB; Molinolo, AA; Schneider, A; Seethala, RR; Vitale-Cross, L; Walline, HM; William, WN, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Curry, J | 1 |
| Alnemri, A | 1 |
| Philips, R | 1 |
| Fiorella, M | 1 |
| Sussman, S | 1 |
| Stapp, R | 1 |
| Solomides, C | 1 |
| Harshyne, L | 1 |
| South, A | 1 |
| Luginbuhl, A | 1 |
| Tuluc, M | 1 |
| Martinez-Outschoorn, U | 1 |
| Argiris, A | 1 |
| Linnenbach, A | 1 |
| Johnson, J | 1 |
| Din-Lovinescu, C | 1 |
| Blitzer, A | 1 |
| Hoppe-Seyler, K | 1 |
| Herrmann, AL | 1 |
| Däschle, A | 1 |
| Kuhn, BJ | 1 |
| Strobel, TD | 1 |
| Lohrey, C | 1 |
| Bulkescher, J | 1 |
| Krijgsveld, J | 1 |
| Hoppe-Seyler, F | 1 |
| Hsu, AT | 1 |
| Hung, YC | 1 |
| Fang, SH | 1 |
| D'Adamo, CR | 1 |
| Mavanur, AA | 1 |
| Svoboda, SM | 1 |
| Wolf, JH | 1 |
| Lindsay, C | 1 |
| Kostiuk, M | 1 |
| Conrad, D | 1 |
| O'Connell, DA | 1 |
| Harris, J | 1 |
| Seikaly, H | 1 |
| Biron, VL | 1 |
| Madera, D | 1 |
| Vitale-Cross, L | 1 |
| Martin, D | 1 |
| Schneider, A | 1 |
| Molinolo, AA | 1 |
| Gangane, N | 1 |
| Carey, TE | 1 |
| McHugh, JB | 1 |
| Komarck, CM | 1 |
| Walline, HM | 1 |
| William, WN | 1 |
| Seethala, RR | 1 |
| Ferris, RL | 1 |
| Gutkind, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Window of Opportunity for Durvalumab (MEDI4736) Plus Metformin Trial of in Squamous Cell Carcinoma of the Head and Neck[NCT03618654] | Phase 1 | 38 participants (Actual) | Interventional | 2018-11-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for metformin and Papillomavirus Infections
| Article | Year |
|---|---|
CD8+ and FoxP3+ T-Cell Cellular Density and Spatial Distribution After Programmed Death-Ligand 1 Check Point Inhibition.
Topics: CD8-Positive T-Lymphocytes; Head and Neck Neoplasms; Humans; Lymphocytes, Tumor-Infiltrating; Metfor | 2023 |
Metformin for the Treatment of Recurrent Respiratory Papillomatosis.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Male; Metformin; Middle Aged; Papillomavirus | 2023 |
Effects of Metformin on the virus/host cell crosstalk in human papillomavirus-positive cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cellular Senescence; Female | 2021 |
Metformin use and the risk of anal intraepithelial neoplasia in type II diabetic patients.
Topics: Anus Neoplasms; Carcinoma in Situ; Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Metformi | 2021 |
Antitumour effects of metformin and curcumin in human papillomavirus positive and negative head and neck cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Curcumin; Gene Expression Regulation, Neoplastic; H | 2019 |
Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Case-Control Studies; Cell Cycle; C | 2015 |